Wyeth/ViroPharma Discontinue Study Of Hep C Drug Due To Elevated Liver Enzymes
This article was originally published in The Pink Sheet Daily
Executive Summary
After Phase II safety signal, next steps for HCV-796 may be lower treatment dose or shorter treatment duration.